David Borg
Family Medicine · Falls City, NENPI 1578502621
Payments from drug & device makers
Across 146 payments — averaging $13.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$961
- AbbVie$158
- Sunovion Pharmaceuticals Inc.$141
- Novo Nordisk$136
- Pfizer$115
- Mylan Specialty L.p.$60
- plus $374 from 16 others
What the payments were for
- Food & beverage$1,946100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 79 | $961 |
| AbbVie | 13 | $158 |
| Sunovion Pharmaceuticals Inc. | 11 | $141 |
| Novo Nordisk | 9 | $136 |
| Pfizer | 8 | $115 |
| Mylan Specialty L.p. | 3 | $60 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $54 |
| Sanofi-aventis U.S. LLC | 3 | $40 |
| Otsuka America Pharmaceutical, Inc. | 2 | $39 |
| Lilly USA, LLC | 2 | $35 |
| Novartis | 2 | $32 |
| Organogenesis Inc. | 1 | $24 |
| Boston Scientific | 1 | $22 |
| Nevro Corp. | 1 | $17 |
| Sanofi Pasteur Inc. | 1 | $17 |
| Biogen | 1 | $17 |
| Sanofi | 1 | $15 |
| E.r. Squibb & Sons, L.L.C. | 1 | $14 |
| Teva Pharmaceuticals USA, Inc. | 1 | $14 |
| Johnson & Johnson | 1 | $13 |
| Acadia Pharmaceuticals Inc | 1 | $12 |
| Boehringer Ingelheim | 1 | $11 |
How this compares
$1,946 in reported general payments places this provider in the 70th percentile of 981 family medicine providers in Nebraska.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 35 | $16,539 |
| RybelsusSemaglutide | 15 | $14,124 |
| XareltoRivaroxaban | 13 | $4,935 |
| Potassium Chloride | 56 | $1,218 |
| Tamsulosin Hcl | 50 | $1,181 |
| Rosuvastatin Calcium | 30 | $877 |
| Lisinopril | 73 | $673 |
| Atorvastatin Calcium | 65 | $601 |
| Metoprolol Succinate | 44 | $587 |
| Losartan Potassium | 55 | $569 |
| Levothyroxine Sodium | 46 | $469 |
| Fluoxetine Hcl | 15 | $452 |
| Levetiracetam | 16 | $431 |
| Warfarin Sodium | 61 | $410 |
| Amlodipine Besylate | 65 | $398 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $115 | $16,53935 claims |
| Novo NordiskRybelsus | $136 | $14,12415 claims |
| Johnson & JohnsonXarelto | $13 | $4,93513 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 981 family medicine providers in Nebraska.
Other family medicine in Falls City
- Brandon EssinkCreighton$92.8M
- Adam BroszGrand Island$60M
- David EnszSouth Sioux City$33.3M
- Allen HuntLincoln$17.2M
- Thomas WolfFremont$8.2M
- William FitzgibbonsElkhorn$7M
- Kenneth BladOmaha$1.6M
- Lorrie McGillPapillion$1.5M
- Ralph HaukeOmaha$657K
- Darin GregoryOmaha$423K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.